SCHEMBL18548810

SCHEMBL18548810

COC(=O)c1c(C)n(C)c2ccc(C(C)C)cc2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
POLB P06746 2/20 0.47
AXL P30530 1/20 0.42
KDM4E B2RXH2 5/20 0.41
MAPT P10636 4/20 0.41
HSD17B10 Q99714 4/20 0.41
HPGD P15428 3/20 0.41
ALOX15 P16050 3/20 0.41
KMT2A Q03164 3/20 0.41
PKM P14618 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
GAA P10253 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 3/20 0.40
ALDH1A1 P00352 4/20 0.39
TSHR P16473 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20291770 0.88 SMN1; SMN2 (0.57) SMN1; SMN2POLBKDM4EMAPTHSD17B10
SCHEMBL18548838 0.84 KDM4E (0.50) SMN1; SMN2POLBAXLKDM4EMAPT
SCHEMBL18548898 0.82 MAPT (0.46) SMN1; SMN2POLBAXLKDM4EMAPT
SCHEMBL18548808 0.79 AXL (0.43) SMN1; SMN2POLBAXLKDM4EMAPT
SCHEMBL5866571 0.72 SMN1; SMN2 (0.63) SMN1; SMN2POLBKDM4EMAPTHSD17B10
SCHEMBL5239507 0.71 ALDH1A1 (0.63) SMN1; SMN2POLBKDM4EMAPTHSD17B10
SCHEMBL5238204 0.71 SMN1; SMN2 (0.52) SMN1; SMN2POLBKDM4EMAPTHSD17B10
SCHEMBL5234885 0.71 SMN1; SMN2 (0.52) SMN1; SMN2POLBKDM4EMAPTHSD17B10
SCHEMBL10086142 0.71 ALDH1A1 (0.58) SMN1; SMN2POLBKDM4EMAPTHSD17B10
SCHEMBL15987388 0.70 SRC (0.56) KDM4EMAPTHSD17B10HPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) 2020-06-16 US disclosed
WO-2017028797-A1 PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER 暨南大学 2017-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683278-B2 Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof NRAS, AXL, ABL1 SMN1; SMN2 4166/4885POLB 2447/4885AXL 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.